Medical Devices - Critical Care Blood Purification
Strategic Profile
CytoSorbents' adsorption technology broadens blood purification applications based on proprietary, biocompatible, and highly porous polymer bead technology designed to reduce elevated levels of harmful compounds from whole blood by hemoadsorption. As part of its strategic plan, CytoSorbents reduced its workforce by approximately 10% and now expects to reach operating cash flow break-even in the first quarter of 2026.
Cyborg Score Rationale
Q3 2025 revenue of $9.5 million increased 10% year-over-year, showing organic growth momentum. However, the company faces near-term challenges with regulatory setbacks on DrugSorb-ATR and cash constraints requiring workforce reductions. A regulatory decision for DrugSorb-ATR is anticipated by mid-2026, with the review expected to focus on remaining open items and may be expedited under the device's FDA Breakthrough Device Designation.
Top Insights
Q3 2025 revenue grew 10% YoY with record performance in distributor territories and near-record performance in direct sales outside core markets.
Company targets Q1 2026 operating cash flow breakeven through 10% workforce reduction and expense realignment.
DrugSorb-ATR De Novo resubmission planned for Q1 2026 with formal FDA meeting expected in late Q4 2025 or early 2026.
Analyst consensus 12-month price target of $5.38 implies 668% upside from current levels.
Named Competitors
Extracorporeal membrane oxygenation (ECMO) systems — Advanced cardiopulmonary support for critical care
Continuous renal replacement therapy (CRRT) — Traditional dialysis and kidney support therapies